Stéphane Leprêtre

6.8k total citations
113 papers, 2.6k citations indexed

About

Stéphane Leprêtre is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Stéphane Leprêtre has authored 113 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Genetics, 52 papers in Pathology and Forensic Medicine and 35 papers in Immunology. Recurrent topics in Stéphane Leprêtre's work include Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (51 papers) and Acute Lymphoblastic Leukemia research (30 papers). Stéphane Leprêtre is often cited by papers focused on Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (51 papers) and Acute Lymphoblastic Leukemia research (30 papers). Stéphane Leprêtre collaborates with scholars based in France, Belgium and Switzerland. Stéphane Leprêtre's co-authors include Hervé Tilly, Aspasia Stamatoullas, Fabrice Jardin, Emmanuel Raffoux, Christian Bastard, Pascal Lenain, Hervé Dombret, Tadeusz Robak, Gérard Buchonnet and Norbert Ifrah and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Stéphane Leprêtre

107 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphane Leprêtre France 29 1.1k 999 674 661 575 113 2.6k
Lode J. Swinnen United States 32 1.5k 1.3× 664 0.7× 931 1.4× 2.4k 3.6× 311 0.5× 110 4.3k
Thomas Klingebiel Germany 31 780 0.7× 520 0.5× 541 0.8× 959 1.5× 328 0.6× 90 3.2k
Matthew A. Lunning United States 29 1.6k 1.4× 592 0.6× 314 0.5× 2.0k 3.0× 223 0.4× 163 3.4k
Olivier Tournilhac France 36 1.9k 1.7× 1.5k 1.5× 1.5k 2.3× 1.5k 2.3× 790 1.4× 180 4.8k
Toshiki Uchida Japan 26 591 0.5× 414 0.4× 675 1.0× 650 1.0× 241 0.4× 86 1.9k
Javier Briones Spain 35 1.3k 1.2× 957 1.0× 1.0k 1.6× 1.9k 2.8× 249 0.4× 161 4.5k
Nicola Fracchiolla Italy 21 476 0.4× 359 0.4× 511 0.8× 599 0.9× 363 0.6× 61 1.9k
Jun Taguchi Japan 29 485 0.4× 354 0.4× 691 1.0× 728 1.1× 232 0.4× 194 2.9k
Tomáš Kozák Czechia 24 1.4k 1.3× 1.1k 1.1× 658 1.0× 637 1.0× 110 0.2× 119 2.7k
H M Lazarus United States 29 435 0.4× 1.1k 1.1× 1.7k 2.6× 1.3k 2.0× 462 0.8× 66 3.8k

Countries citing papers authored by Stéphane Leprêtre

Since Specialization
Citations

This map shows the geographic impact of Stéphane Leprêtre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Leprêtre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Leprêtre more than expected).

Fields of papers citing papers by Stéphane Leprêtre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Leprêtre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Leprêtre. The network helps show where Stéphane Leprêtre may publish in the future.

Co-authorship network of co-authors of Stéphane Leprêtre

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Leprêtre. A scholar is included among the top collaborators of Stéphane Leprêtre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Leprêtre. Stéphane Leprêtre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roos‐Weil, Damien, Cécile Tomowiak, Stéphanie Poulain, et al.. (2025). Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines. European Journal of Cancer. 232. 116120–116120.
2.
Tomowiak, Cécile, Stéphanie Poulain, Pierre Feugier, et al.. (2024). Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia. Annals of Hematology. 104(1). 685–690. 2 indexed citations
3.
4.
Tomowiak, Cécile, Stéphanie Poulain, Charles Herbaux, et al.. (2021). Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Advances. 5(9). 2438–2446. 21 indexed citations
5.
Lequesne, Justine, Pascal Lenain, Nathalie Contentin, et al.. (2021). Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study. European Journal Of Haematology. 106(6). 788–799. 2 indexed citations
6.
Touzart, Aurore, Étienne Lengliné, Mohamed Belhocine, et al.. (2019). Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research. 25(8). 2483–2493. 28 indexed citations
7.
Camus, Vincent, Sydney Dubois, Pierre‐Alain Thiébaut, et al.. (2019). Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21‐year‐old patient: A case report and review. SHILAP Revista de lepidopterología. 7(6). 1171–1177. 1 indexed citations
8.
Camus, Vincent, Sydney Dubois, Stéphane Leprêtre, Fabrice Jardin, & Hervé Tilly. (2018). Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient. Clinical Case Reports. 6(8). 1418–1421. 4 indexed citations
9.
Leprêtre, Stéphane, Carlos Graux, Aurore Touzart, Elizabeth Macintyre, & Nicolas Boissel. (2017). Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators. Experimental Hematology. 51. 7–16. 21 indexed citations
10.
Loschi, Michaël, Ali N. Chamseddine, Nathalie Contentin, et al.. (2015). Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients. Mycopathologia. 179(5-6). 337–345. 13 indexed citations
11.
Leprêtre, Stéphane, et al.. (2015). Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leukemia & lymphoma. 57(4). 852–865. 4 indexed citations
12.
Cornet, Édouard, Cécile Tomowiak, Aline Schmidt, et al.. (2014). Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology. 166(3). 390–400. 42 indexed citations
13.
Benhamou, Y., Stéphane Leprêtre, Edith Köning, et al.. (2014). Hématome intra-hépatique spontané : une étiologie inattendue. La Revue de Médecine Interne. 36(2). 127–130. 2 indexed citations
14.
Berceanu, Ana, Stéphane Leprêtre, Mario Ojeda‐Uribe, et al.. (2011). Prophylaxie antibactérienne et antifongique chez les patients à haut risque en hématologie Enquête de pratique et forum. Hématologie. 17(4). 3–15. 1 indexed citations
15.
Leprêtre, Stéphane, Ann Janssens, Véronique Leblond, et al.. (2011). The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leukemia & lymphoma. 53(5). 820–829. 4 indexed citations
16.
Modzelewski, Romain, Stéphane Leprêtre, Olivier Martinaud, et al.. (2010). Brain Perfusion in Adult Patients with Acute Myeloblastic Leukemia before and after Cytosine Arabinoside. Molecular Imaging and Biology. 13(4). 747–753. 3 indexed citations
17.
Maloum, Karim, Catherine Settegrana, Élise Chapiro, et al.. (2009). IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Annals of Hematology. 88(12). 1215–1221. 23 indexed citations
18.
Baleydier, Frédéric, Anne‐Valérie Decouvelaere, Julie Bergeron, et al.. (2008). T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome. Clinical Cancer Research. 14(3). 692–700. 30 indexed citations
19.
Coiffier, Bertrand, Stéphane Leprêtre, Lars Møller Pedersen, et al.. (2007). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 111(3). 1094–1100. 287 indexed citations
20.
Leprêtre, Stéphane & Éric Van Den Neste. (2006). Place de la chimiothérapie dans la leucémie lymphoïde chronique. Hématologie. 12(6). 28–34.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lode J. Swinnen Breakdown of academic impact, for papers by Thomas Klingebiel Breakdown of academic impact, for papers by Matthew A. Lunning Breakdown of academic impact, for papers by Olivier Tournilhac Breakdown of academic impact, for papers by Toshiki Uchida Breakdown of academic impact, for papers by Javier Briones Breakdown of academic impact, for papers by Nicola Fracchiolla Breakdown of academic impact, for papers by Jun Taguchi Breakdown of academic impact, for papers by Tomáš Kozák Breakdown of academic impact, for papers by H M Lazarus
Rankless by CCL
2026